Since he joined Qatar University in 2013, Dr.Hazem has secured over 1 million Qatari Riyal for clinical and translational research projects that focus on the applications of pharmacogenomics especially in the field of cardiovascular disease. His research projects helped define the impact of genetics on warfarin dosing, clopidogrel efficacy and safety in Arabs and more specifically in the Qatari population. He also published the first Genome Wide Association study (GWAS) on warfarin dosing in the MENA region. His ultimate goal is to spread the knowledge on the applications of genetics in the healthcare system and to launch a pharmacist-led pharmacogenetic service at Hamad Medical Corporation, the main care provider facility in Qatar. Aside from genomics, Dr.Elewa and his group conducted multiple clinical research studies in the area of cardiology and anticoagulation.